U.S. Markets open in 8 hrs 16 mins
  • S&P Futures

    3,256.25
    +18.25 (+0.56%)
     
  • Dow Futures

    26,869.00
    +154.00 (+0.58%)
     
  • Nasdaq Futures

    10,950.00
    +58.25 (+0.53%)
     
  • Russell 2000 Futures

    1,460.40
    +13.40 (+0.93%)
     
  • Crude Oil

    40.55
    +0.24 (+0.60%)
     
  • Gold

    1,875.50
    -1.40 (-0.07%)
     
  • Silver

    23.36
    +0.17 (+0.73%)
     
  • EUR/USD

    1.1673
    -0.0003 (-0.0233%)
     
  • 10-Yr Bond

    0.6660
    0.0000 (0.00%)
     
  • Vix

    28.51
    -0.07 (-0.24%)
     
  • GBP/USD

    1.2755
    +0.0003 (+0.0217%)
     
  • BTC-USD

    10,682.86
    -77.73 (-0.72%)
     
  • CMC Crypto 200

    217.49
    +8.55 (+4.09%)
     
  • FTSE 100

    5,822.78
    -76.48 (-1.30%)
     
  • Nikkei 225

    23,220.50
    +132.68 (+0.57%)
     

Aldeyra Therapeutics to Participate in Upcoming Virtual Investor Conferences

Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra) today announced that senior management will be presenting and hosting 1x1 meetings at the following virtual investor conferences in August:

  • BTIG Virtual Biotechnology Conference 2020
    Presentation Date: Tuesday, August 11, 2020
    Time: 11:30 a.m. ET

  • 2020 Wedbush PacGrow Healthcare Virtual Conference
    Presentation Date: Wednesday, August 12, 2020
    Time: 12:35 p.m. ET

A live webcast of these presentations will be available on the investor relations page of the company’s corporate website at https://ir.aldeyra.com. After the live webcast, the events will remain archived on the Aldeyra Therapeutics website for 90 days.

About Aldeyra Therapeutics

Aldeyra Therapeutics is a clinical-stage biotechnology company focused on the development of novel therapies with the potential to improve the lives of patients with immune-mediated diseases. Two of the company’s lead compounds, reproxalap and ADX-629, target reactive aldehyde species (RASP), which are elevated in ocular and systemic inflammatory disease, leading to elevated levels of cytokine release via activation of a broad array of inflammatory factors, including NF-κB, inflammasomes, and Scavenger Receptor A. Reproxalap is being evaluated in Phase 3 clinical trials in patients with dry eye disease and allergic conjunctivitis. The company’s clinical pipeline also includes ADX-2191, a dihydrofolate reductase inhibitor in Phase 3 testing for proliferative vitreoretinopathy, and ADX-1612, a chaperome inhibitor in Phase 2 testing for COVID-19 and ovarian cancer. For more information, visit https://www.aldeyra.com/ and follow us on LinkedIn, Facebook, and Twitter.

View source version on businesswire.com: https://www.businesswire.com/news/home/20200804005249/en/

Contacts

Corporate Contact:
David McMullin
Aldeyra Therapeutics, Inc.
Tel: 781-761-4904 ext. 218
dmcmullin@aldeyra.com

Investor & Media Contact:
Scott Solomon
Sharon Merrill Associates, Inc.
Tel: 617-542-5300
ALDX@investorrelations.com